PTC Therapeutics, Inc. (PTCT)

34.16 +2.01 (+6.25%) 收市：04:00PM EDT

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 988

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director	1.24M	無	1973
Dr. Stuart W. Peltz Ph.D.	Co-Founder, Senior Consultant & Member of Scientific Advisory Board	796.9k	無	1960
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director	145k	無	1946
Dr. Neil Almstead Ph.D.	Chief Technical Operations Officer	829.97k	無	1967
Mr. Eric Pauwels	Chief Business Officer	761.18k	無	1961
Mr. Pierre Gravier M.S.	Chief Financial Officer	619.92k	無	1986
Ms. Christine Utter	Senior VP, Chief Accounting Officer & Head of People Services	595.54k	995.57k	1978
Alex Kane	Investor Relations Officer	無	無	無
Mr. Mark Elliott Boulding	Executive VP & Chief Legal Officer	761.94k	1.27M	1961
Ms. Jane Baj	Vice President of Corporate Communications	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

公司管治

截至 2024年4月29日 止，PTC Therapeutics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：7；董事會：2；股東權利：7；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。